ArticleExpert opinion on pharmacotherapy2014
An update on male hypogonadism therapy.
Article in Expert opinion on pharmacotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis.BMC urology · 2025Pooled it
- Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.Archives of endocrinology and metabolism · 2025Pooled it
- Effectiveness of clomiphene citrate on total motile sperm count and hormonal profile in men with clinical infertility.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Real-World Prescribing Patterns of Clomiphene Citrate for Male Infertility: A National Cross-Sectional Survey of Urologists in Türkiye.Journal of clinical medicine · 2026Article
- The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice.The world journal of men's health · 2023Review
- Clomiphene citrate: A potential alternative for testosterone therapy in hypogonadal males.Endocrinology, diabetes & metabolism · 2023Article
- Strategies to Increase Testosterone in Men Seeking Fertility.Urology research & practice · 2023Article
- Elevated HCG and retroperitoneal adenopathy after clomiphene therapy for infertility.BMJ case reports · 2022Article
- Advances in stem cell research for the treatment of primary hypogonadism.Nature reviews. Urology · 2021Review
- Hypogonadism induced by surgical stress and brain trauma is reversed by human chorionic gonadotropin in male rats: A potential therapy for surgical and TBI-induced hypogonadism?Endocrinology, diabetes & metabolism · 2021Article
- Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review.ClinicoEconomics and outcomes research : CEOR · 2021Review
- Male Contraception.The Yale journal of biology and medicine · 2020Review
- Gender affirming medical care of transgender youth.Current problems in pediatric and adolescent health care · 2019Article
- Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?Neuroscience and biobehavioral reviews · 2019Review
- Novel Therapy for Male Hypogonadism.Current urology reports · 2018Review
- A Case of Male Osteoporosis: A 37-Year-Old Man with Multiple Vertebral Compression Fractures.Case reports in endocrinology · 2017Article
- Enclomiphene citrate for the treatment of secondary male hypogonadism.Expert opinion on pharmacotherapy · 2016Review
- Effect ofAvicenna journal of phytomedicineArticle
- Male Hormonal Contraception: Where Are We Now?Current obstetrics and gynecology reportsReview
- Human Chorionic Gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone > 300 ng/dL.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionMen who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. AREAS COVERED: Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. EXPERT OPINION: Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.